RADX
$4.86
Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs.
Recent News
Favourable Signals For Radiopharm Theranostics: Numerous Insiders Acquired Stock
Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like...
Radiopharm (RADX) Sees Slight Pessimism From Analysts
We recently published 7 Best ASX Stocks to Buy Right Now. Radiopharm Theranostics Limited (NASDAQ:RADX) is one of the best ASX stocks. Radiopharm Theranostics Limited (NASDAQ:RADX) is a biotechnology company developing treatments for ailments such as brain metastasis and prostate cancer. B. Riley lowered its share price target for the firm to $13 from $15 and […]
Top Midday Gainers
Radiopharm Theranostics (RADX) said Monday that interim data from its phase 2b clinical trial of RAD
Radiopharm Theranostics Expects to Raise $22.7 Million Via Private Placement, Shares Down Pre-Bell
Radiopharm Theranostics (RADX) shares were down over 15% in recent Monday premarket activity after t
Radiopharm receives DSMC recommendation to advance Phase 1 ‘HEAT’ trial
Radiopharm (RADX) Theranostics announced that it has received a positive recommendation from the Data Safety and Monitoring Committee to advance its clinical-stage radiotherapeutic asset, 177Lu-RAD202, to the next dose level of 75mCi in the Phase 1 ‘HEAT’ clinical trial in patients with Human Epidermal Growth Factor Receptor 2-positive advanced solid tumors. The DSMC is a multidisciplinary committee that conducts detailed reviews of study data, discusses potential safety events and provides reco